Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call
Despite a net loss, Lexicon Pharmaceuticals Inc (LXRX) shows promising advancements in drug development and strategic financial maneuvers.
Lexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?